{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["207(3)"],"submitter":["Jo T"],"pubmed_abstract":["Efficacy of chimeric antigen receptor (CAR) T-cell therapy hinges on CAR-T potency, as well as on tumour traits and disease status. Potency assessment currently relies on post-infusion in vivo growth; therefore, manufacturing metrics could provide early potency predictions, enabling potency-guided strategies. To assess the impact of ex vivo cell growth during manufacturing on clinical outcomes, we analysed diffuse large B-cell lymphoma patients treated with tisagenlecleucel, merging clinical records with manufacturing parameters. Of 75 cases, 21 (28%) showed poor growth, indicated by any decrease in cell number during manufacturing. Good growth correlated with significantly better overall response rate (85.2% vs. 52.4%; p = 0.006), with enhanced lymphocyte increase in peripheral blood afte"],"journal":["British journal of haematology"],"pagination":["1002-1010"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12436216"],"repository":["biostudies-literature"],"pubmed_title":["Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy."],"pmcid":["PMC12436216"],"pubmed_authors":["Kitawaki T","Mizumoto C","Shimizu T","Takaori-Kondo A","Kanda J","Jo T","Nagao M","Arai Y","Nishikori M","Yamashita K","Sakamoto T"],"additional_accession":[]},"is_claimable":false,"name":"Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy.","description":"Efficacy of chimeric antigen receptor (CAR) T-cell therapy hinges on CAR-T potency, as well as on tumour traits and disease status. Potency assessment currently relies on post-infusion in vivo growth; therefore, manufacturing metrics could provide early potency predictions, enabling potency-guided strategies. To assess the impact of ex vivo cell growth during manufacturing on clinical outcomes, we analysed diffuse large B-cell lymphoma patients treated with tisagenlecleucel, merging clinical records with manufacturing parameters. Of 75 cases, 21 (28%) showed poor growth, indicated by any decrease in cell number during manufacturing. Good growth correlated with significantly better overall response rate (85.2% vs. 52.4%; p = 0.006), with enhanced lymphocyte increase in peripheral blood afte","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-04-08T19:53:01.331Z","creation":"2026-04-08T14:35:53.717Z"},"accession":"S-EPMC12436216","cross_references":{"pubmed":["40633933"],"doi":["10.1111/bjh.20266"]}}